



Integrating Diagnostic Work-up into Lung Cancer Screening

David F. Yankelevitz, MD

Disclosures

- I am a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by Cornell Research Foundation (CRF). Some of these are licensed to GE and I receive compensation related to this.



Knowledge Base

- Small
- Solitary
- Nodules

Knowledge Base

- Small
- Solitary
- Nodules
- Diagnostic Work-up

Knowledge Base

- Small
- Solitary
- Nodules
- Diagnostic Work-up
 - Quantitative Imaging



Panel

- Frank Detterbeck, MD, FACS, FCCCP, *Yale Medical Group*
- Gianluca Paladini, PhD, *Siemens Innovation Center*
- Charles A. Powell, MD, *Mt Sinai Medical Center*
- Susan A. Wood, PhD, *Vida Diagnostics*



Panel

- Frank Detterbeck, MD, FACS, FCCCP, *Yale Medical Group*
- Gianluca Paladini, PhD, *Siemens Innovation Center*
- Charles A. Powell, MD, *Mt Sinai Medical Center*
- Susan A. Wood, PhD, *Vida Diagnostics*

Critical considerations in the workup of Screen detected pulmonary nodules

- Main concerns regarding workup
 - How frequently might a finding be expected to be malignant
 - If malignant, at what point might it be possible to measure change
 - What might be the downside of waiting




Critical considerations in the workup of Screen detected pulmonary nodules

- Discussion about nodule size cutoff for determining positive result
- Growth rates of tumors (baseline versus repeat, sub-solid versus solid)
- Development of protocols, how can we proceed

Critical considerations in the workup of Screen detected pulmonary nodules

- Technical developments, what will be required to advance the field
 - Hardware (improved resolution, lower dose, dual energy)
 - Software (Improved detection)



“You have enemies? Good. That means you've stood up for something, sometime in your life.”

Winston Churchill